Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a singular 137.52% summation implicit the past year, though the banal has pulled backmost 6.12% year-to-date and sits 7.20% beneath its one-month high, presently trading adjacent $72.70. The banal remains good disconnected its 52-week precocious of $86.74, with the Street's statement people sitting astatine $93.90 crossed 22 analysts.

Barclays stands isolated from the pack, raising its terms people to $106 from $95 portion maintaining an Overweight standing connected the shares. That people represents astir 46% upside from existent levels and sits meaningfully supra the Street's average. But tin IONS realistically scope $106 by the extremity of 2026?

The Barclays thesis centers connected a azygous underappreciated asset. The steadfast boosted its 2034 Tryngolza estimation for terrible hypertriglyceridemia (sHTG) to $4 cardinal successful the U.S., supported by what it describes arsenic "supportive" doc checks. Barclays argues that terrible hypertriglyceridemia is the astir important near-term accidental for Ionis and remains underappreciated by the market. The sNDA for olezarsen successful sHTG carries a PDUFA people day of June 30, 2026, making the catalyst timeline factual and near-term.

Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin retire earlier than expected.

1. Olezarsen's wide sHTG motorboat opportunity: The sHTG statement targets a wide diligent population, expanding good beyond the constrictive familial chylomicronemia syndrome denotation covered by Tryngolza. Phase 3 CORE and CORE2 trials demonstrated up to 72% placebo-adjusted simplification successful fasting triglycerides and an 85% simplification successful acute pancreatitis events, a objective illustration that supports premium pricing and durable gross compounding for status portfolios.

2. Tryngolza's accelerating commercialized trajectory: Net merchandise income deed $50 cardinal successful Q4 2025, a 56% sequential increase, with full-year 2025 income of $108 million. That ramp from $6 cardinal successful Q1 to $50 cardinal successful Q4 demonstrates the benignant of motorboat execution that builds semipermanent royalty and gross durability.

3. Pipeline catalysts stacked done 2026: Zilganersen for Alexander illness received FDA Priority Review with a PDUFA day of September 22, 2026. Mid-year information from the pelacarsen Lp(a) HORIZON cardiovascular outcomes proceedings and the eplontersen CARDIO-TTRansform proceedings successful H2 2026 supply aggregate shots astatine worth instauration for semipermanent holders.